… EGFR mutations were screened retrospectively. This multicentre study was conducted at
three … The patients received gefitinib or erlotinib as the first-line therapy were classified as …

… was also assessed retrospectively and the impact of some key drugs on OS was evaluated.
… Twelve patients went back on gefitinib and 32 received erlotinib in one of their later-line …

… bias due to the retrospective design of our study and Korean study. … erlotinib/gefitinib arm
is the other limitation of our study. Despite all of these limitations, this study is one of the studies …

… EGFR-TKI combination is 250 mg gefitinib once a day, 150 mg erlotinib once a day, 125 mg
… A retrospective multicenter study by Bi N et al 9 showed that first-line TKI combined with RT …

… Methods: We performed a retrospective analysis of pooled … A Phase II study of another
EGFR TKI, erlotinib, in unselected … A prospective, multicenter study of elderly patients with the …

… with gefitinib and erlotinib. Consequently, we aimed to conduct a nationwide study (ARISE
study) … The main limitation of this study was the nature of the retrospective study design and …

… The data from the retrospective analysis of BR.21 trial about erlotinib in pretreated patients
suggest that never-smokers and patients with EGFR-positive tumors might experience an …

… 2010, we retrospectively evaluated the efficacy and toxicity of erlotinib administered as the
… our study failed to respond to erlotinib. Shukuya et al. (23) reported the efficacy of gefitinib for …

… benefit from treatment with erlotinib or other EGFR TKIs (eg, afatinib, gefitinib) than do those
… Another retrospective study analyzed 1086 patients for EGFR mutations and identified 27 …

… Several retrospective studies have revealed that various EGFR‐TKIs (erlotinib, gefitinib,
or afatinib) are effective for treating leptomeningeal metastases (LM) from NSCLC in patients …